Biotech entity
All 2 tracked stories fall under one category: pharma. Codexis is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 14-day span, the pace is roughly 1 story per week. Their average consequence score of 5 runs below the beat's 6.1 for that window.
Last mentioned: Mar 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. Codexis is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 14-day span, the pace is roughly 1 story per week. Their average consequence score of 5 runs below the beat's 6.1 for that window. Source depth averages 2 original sources per story, versus 3.4 across the same-window beat baseline. This profile follows 2 Biotech stories mentioning Bachem across the period from March 11, 2026 to March 24, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 209 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bachem. Shared-story counts are live from our verified record — not editorial picks.
Analyst Sentiment Review
Major firms maintain ratings, citing steady execution of the strategic pivot.
2026 Guidance Issued
Management outlines $72M-$76M revenue target driven by ECO Synthesis.
Q4 2025 Earnings Release
Codexis reports significant beats on both top and bottom lines.
Codexis (CDXS) has maintained steady analyst sentiment following a strong Q4 2025 performance that exceeded revenue and earnings expectations. The company’s strategic pivot toward its ECO Synthesis platform for RNA manufacturing is gaining commercial traction, supported by a 2026 revenue target of $72M–$76M.
Source: finance.yahoo.com · insidermonkey.com
Bachem (BCHMF) is set to release its quarterly earnings this Thursday, with investors closely monitoring the Swiss CDMO's ability to scale production for the booming GLP-1 market. As a critical supplier of peptides and oligonucleotides, Bachem's financial performance and capacity expansion updates will serve as a bellwether for the broader weight-loss drug supply chain.
Source: themarketsdaily.com · tickerreport.com
Bachem is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
